Dr Reddy's Labs — 360° view

Dr Reddy's Labs, a company in the Pharmaceuticals industry, reported revenue of ₹8,698 crore and net profit of ₹913 crore for the September 2026 quarter.

Dr Reddy's Labs (NSE: DRREDDY) closed at ₹1,390.20 on 20 Nov 2026, up 11.3% over the past year. Its market capitalisation is ₹1,16,119 crore and it trades at 41.5 times earnings.

Share price
₹1,390.20 (20 Nov 2026)
Market cap
₹1,16,119 Cr (20 Nov 2026)
P/E
41.47 (20 Nov 2026)
Revenue
₹8,698 Cr (September 2026 quarter)
Net profit
₹913 Cr (September 2026 quarter)
ROCE
13.0% (FY26)
ROE
11.2% (FY26)
Book value
₹465 (FY26)
Dividend yield
0.58% (last 12 months to 20 Nov 2026)
52-week high / low
₹1,414.90 / ₹1,101.00 (20 Nov 2026)
1-year return
11.3% (to 20 Nov 2026)
Sector
Healthcare
Industry
Pharmaceuticals
Symbol
NSE: DRREDDY

Dr. Reddy's Laboratories Ltd is a leading India-based pharmaceutical company which offers a portfolio of products and services, including Active Pharmaceutical Ingredients (APIs), Custom Pharmaceutical services (CPS), generics, biosimilars and differentiated formulations.

Descriptive research only, not investment advice. Evenstocks is not a SEBI-registered investment adviser.